A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== Malaysian and Singaporean === Malays from Malaysia, using the Malay dialect similar to Indonesian, use the word kicap for soy sauce. Kicap is traditionally of two types: kicap lemak (lit "fat/rich soy sauce") and kicap cair. Kicap lemak is similar to Indonesian kecap manis but with very much less sugar, while kicap cair is the Malaysian equivalent of kecap asin.
As agreed at the Potsdam Conference, 200,000 troops of the Chinese 1st Army occupied northern Indochina to the 16th parallel, while the British under the South-East Asia Command of Lord Mountbatten occupied the south. The Chinese troops had been sent by Chiang Kai-shek under General Lu Han to accept the surrender of Japanese forces occupying that area, then to supervise the disarming and repatriation of the Japanese Army. In the North, the Chinese permitted the DRV government to remain in charge of local administration and food supply. Initially, the Chinese kept the French Colonial soldiers interned, with the acquiescence of the Americans. The Chinese used the VNQDĐ, the Vietnamese branch of the Chinese Kuomintang, to increase their influence in Indochina and put pressure on their opponents. Chiang Kai-shek deliberately withheld his best soldiers from Vietnam, holding them in reserve for the fight against the Communists inside China, and instead sent undisciplined warlord troops from Yunnan under Lu Han to occupy Vietnam north of the 16th parallel and accept the Japanese surrender. In total, 200,000 of General Lu Han's Chinese soldiers occupied north Vietnam starting August 1945. 90,000 arrived by October, the 62nd army came on 26 September to Nam Dinh and Haiphong, later arriving at Lang Son and Cao Bang and the Red River region and Lai Cai were occupied by a column from Yunnan. Vietnamese VNQDD fighters accompanied the Chinese soldiers. Lu Han occupied the French governor general's palace after ejecting the French staff under Sainteny.
=== Discovery === The first chemical compounds of the cephalosporin group were isolated from Cephalosporium acremonium, a cephalosporin-producing fungus first discovered by Giuseppe Brotzu in 1948 from a sewage outfall off the Sardinian coast. From crude filtrates of the Cephalosporium acremonium culture scientists got new antibacterial activity. It was noted that the crude filtrate could inhibit the growth of Staphylococcus aureus.
Sources: en.wikipedia.org
== Further reading == Valera, Maria José; Torija, Maria Jesús; Mas, Albert; Mateo, Estibaliz (2013). "Acetobacter malorum and Acetobacter cerevisiae identification and quantification by Real-Time PCR with TaqMan-MGB probes". Food Microbiology. 36 (1): 30–39. doi:10.1016/j.fm.2013.03.008. ISSN 0740-0020. PMID 23764217. Sagarzazu, Noelia Isabel, et al. "Optimization of denaturing high performance liquid chromatography technique for rapid detection and identification of acetic acid bacteria of interest in vinegar production." Acetic Acid Bacteria 2.1s (2013): e5. Ogawa S, Tachimoto H, Kaga T (January 2010). "Elevation of ceramide in Acetobacter malorum S24 by low pH stress and high temperature stress". Journal of Bioscience and Bioengineering. 109 (1): 32–6. doi:10.1016/j.jbiosc.2009.07.007. PMID 20129078.
A branded version called Cortrosyn, which was created and developed by Organon and was approved by the FDA in 1970, and as of January 2017 was under the control of Amphastar Pharmaceuticals, and there were three generic versions under ANDAs, one for Mylan approved in 2009, one for Sandoz/Novartis, approved in 2012, and another for Amphastar under ANDA 016750. This version is a powder that is reconstituted before use. A version of cosyntropin in solution (as opposed to powder) was developed by Sandoz/Novartis and was approved under the 505b(2) pathway in 2008; as of January 2017 it had been discontinued. In the UK, available forms of tetracosactide/cosyntropin, the synthetic form of corticotrophin, have been approved for both therapeutic and diagnostic uses, and have included:
inverted repeat A nucleotide sequence followed downstream on the same strand by its own reverse complement. The initial sequence and the reverse complement may be separated by any number of nucleotides, or may be immediately adjacent to each other; in the latter case, the composite sequence is also called a palindromic sequence. Inverted repeats are self-complementary by definition, a property which involves them in many biological functions and dysfunctions. Contrast direct repeat.
-sheet, or coil secondary structures. Backbone-dependent rotamer libraries present conformations and/or frequencies dependent on the local backbone conformation as defined by the backbone dihedral angles
Sources: en.wikipedia.org
Spectroscopy with a variable pathlength cell takes advantage of Beer–Lambert law to determine concentrations of various solutions. By knowing the molar absorptivity of the material and varying the path length, absorption can be plotted as a function of path length. See sample plot to the right: By taking a linear regression of the linear plot above an expression relating Absorbance, A, slope, m, pathlength and concentration can be derived. A linear equation of two variables can be derived,
Amy Walter, editor of the nonpartisan The Cook Political Report, also argued that the electoral environment was inherently difficult for Harris because the top issue for voters was inflation during the Biden-Harris administration. Ronald Brownstein of The Atlantic, who spoke with members of Harris's campaign, argued that the extent of Biden's unpopularity and public discontent with the economy proved too much for Harris to overcome. Brownstein compared the election to the 1968 presidential election (when unpopular incumbent Lyndon B. Johnson withdrew from the race and Vice President Hubert Humphrey lost to Richard Nixon) and the 1980 presidential election (when unpopular incumbent Jimmy Carter lost to Ronald Reagan due to stagflation and the 1970s energy crisis). Members of Harris' campaign stated after the election that their internal polling never showed Harris ahead of Trump and they did not believe that Harris was the favorite to win the election. David Plouffe, a senior campaign advisor to Harris, claimed that even making the race competitive was a win for Harris' staff. The opportunity to elect Harris as the first female U.S. president proved to be less important to voters than issues like the economy and immigration. Results of VoteCast, as reported by Fox News, find that 13% of voters chose "the fact that Kamala Harris would be the first female president" as the single most important factor to their vote. Even so, polls have shown that voters support backing a female candidate while also acknowledging the challenges they might face on the campaign trail.
=== EC 1.20.4 Acting on phosphorus or arsenic in donors, with disulfide as acceptor === EC 1.20.4.1: arsenate reductase (glutaredoxin) EC 1.20.4.2: methylarsonate reductase EC 1.20.4.3: mycoredoxin EC 1.20.4.4: arsenate reductase (thioredoxin)
Histology image: 08601ooa – Histology Learning System at Boston University - "Integument: scalp, transverse" Histology image: 08801ooa – Histology Learning System at Boston University - "Integument: scalp" lesson1 at The Anatomy Lesson by Wesley Norman (Georgetown University) http://www.dartmouth.edu/~humananatomy/figures/chapter_47/47-1.HTM Archived 2016-04-30 at the Wayback Machine
=== Detection in biological fluids === Tramadol and desmetramadol may be quantified in blood, plasma, serum, or saliva to monitor for abuse, confirm a diagnosis of poisoning or assist in the forensic investigation of a sudden death. Most commercial opiate immunoassay screening tests do not cross-react significantly with tramadol or its major metabolites, so chromatographic techniques must be used to detect and quantify these substances. The concentration of desmetramadol in the blood or plasma of a person who has taken tramadol is generally 10–20% that of the parent drug.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.